Multiple Sclerosis

View All

Pharma News for Exelixis, AstraZeneca, Kyverna
BMS, and Exelixis’s Opdivo + CABOMETYX in First-Line Advanced Renal Cell Carcinoma; AIRSUPRA Now Available as the First and Only FDA-approved Anti-inflammatory Rescue Option for Asthma; AstraZeneca’s Voydeya Receives First-ever Regulatory Approval; EMA Grants ODD to GC Biopharma’s Sanfilippo Syndrome (Type A) Treatment; FDA Approves NRx Pharma’s IND Application of NRX-101; FDA Fast Track Designation to Kyverna’s KYV-101

Opdivo in Combination with CABOMETYX Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma Bristol Myers Squibb and Exelixis, Inc. have released the four-year follow-up findings from the CheckMate -9ER trial, which investiga...

Find More

multiple-sclerosis-treatment
Revolutionizing Multiple Sclerosis Treatment: A New Era of Therapies

Multiple sclerosis is an unpredictable, autoimmune disease that affects the central nervous system. Multiple sclerosis is believed to impact almost 1 million Americans, and the disease manifests itself in a variety of ways. Because nerves are affected in different ways and exhibit a variety of symptoms, no two case...

Find More

Pharma News and Updates for Gilead, Biogen, Pfizer, MediWound, UCB
Gilead Buys Out Rights to Cancer Therapy from Jounce; FDA Places Clinical Hold on Biogen’s Orelabrutinib; Pfizer Announces Phase 3 BENEGENE-2 Study Result; FDA Approves MediWound’s NexoBrid; UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab; FDA Approves TG Therapeutics’ Briumvi

Gilead Buys Out Rights to Cancer Therapy from Jounce for USD 67 Million Gilead Sciences must have liked what it saw in a two-year-old collaboration with Jounce Therapeutics for CCR8-targeting cancer immunotherapy because the company has just agreed to own the program fully. The drug in question, GS-1811 (formerl...

Find More

Pharma News for Sanofi, Bayer, Spero
AstraZeneca’s Imfinzi Shows Positive Results; Novartis Announces Results of Tislelizumab; FDA Grants Orphan Drug Designation to Evorpacept; EU Approves Sanofi’s Xenpozyme; Bayer’s Kerendia Approves in China; FDA Breakthrough Therapy Designation to Talquetamab; FDA Puts Clinical Hold on Sanofi’s Tolebrutinib; FDA Rejects Spero’s Tebipenem

FDA Grants Orphan Drug Designation to Evorpacept for AML ALX Oncology Holdings announced that the U.S. Food and Drug Administration had granted orphan drug designation to Evorpacept, a next-generation CD47 blocker, for treating patients with acute myeloid leukemia (AML). Acute Myeloid Leukemia (AML) is an agg...

Find More

Latest MedTech News and Updates for Abbott, Philips and HOYA
Abbott’s Alinity m STI Assay; Phillips’ MR 7700 System; HOYA’s MiYOSMART Spectacle Lens; Magneto’s Pulmonary Embolism Treatment; Owen Mumford and Stevanto Group’s Collaboration Deal; Elekta’s Radiosurgery System-Elekta Esprit

Abbott Receives Regulatory Approval from US FDA for Alinity™ m STI Assay On May 04, 2022, the US Food and Drug Administration (FDA) granted the regulatory approval to Alinity™ m STI Assay developed by Abbott which is capable of simultaneously detecting and differentiating four common sexually trans...

Find More

recent-pharma-biotech-news-updates-for-fosun-biontech-biomarin-Boston-Scientific
Fosun-BioNTech’s COVID-19 vaccine; Multiple Sclerosis research update; Vosoritide nabs FDA review; FDA nods to paclitaxel-coated Ranger balloon for PAD

FDA nods Boston Scientific's paclitaxel-coated Ranger balloon for peripheral artery disease Boston Scientific has received the FDA approval for its Ranger paclitaxel-coated balloon, designed to restrict a patient's systemic exposure to the chemotherapy used to reduce the closure of reopened arteries. The slim...

Find More

Burden of Neurodegenerative Disorders
The Growing Burden Of Neurodegenerative Disorders

Neurodegenerative diseases affect millions of people worldwide. And with the world demographics getting older, it is apt to foretell that the burden of neurodegenerative disorders is expected to mount. With advances in medical technology, the life expectancy of people has drastically increased, reeling people to an...

Find More

latest pharma news
MorphoSys, Incyte receive FDA Ok for Monjuvi; Siemens Healthineers set to buy Varian; Immunic’s IMU-838 promising results

MorphoSys, Incyte gets an early FDA nod for Monjuvi, an alternative to CAR-T for B-cell malignancies MorphoSys and Incyte announced the US FDA approval under accelerated approval for their treatment Monjuvi in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymp...

Find More

pharma-news
CanSino deals with Precision; Atea raises USD 215 M; Applied Molecular Transport targets for USD 100 M IPO; Cell therapy repairs multiple sclerosis in mice

CanSino adds mRNA with Precision NanoSystems  CanSino Biologics is already evaluating a recombinant coronavirus vaccine in China. However, it is adding the mRNA to COVID-19 vaccine through a licensing agreement with Precision NanoSystems. The partners will work on an mRNA nanoparticle vaccine for COVID-1...

Find More

Marijuana
Marijuana as a treatment approach

Cannabis sativa or Cannabis indica is commonly known as Medical marijuana or cannabis (cannabinoids) are prescribed by physicians to their patients, to treat diseases, conditions or to relieve pain or symptoms. As per the National Institute of Health, Marijuana or cannabis is used for the treatment of ailments for ...

Find More